What is Erickson Laboratories?
Erickson Laboratories operates at the intersection of medical craftsmanship and patient-centric healthcare, specializing in the design and fabrication of custom ocular prosthetics. With a legacy spanning over eight decades, the firm has established a robust market position by prioritizing both aesthetic realism and functional motility. By maintaining a dual-location presence in Seattle and Tacoma, the company ensures consistent, high-touch service delivery. Their business model relies on the meticulous work of skilled ocularists who translate complex anatomical requirements into comfortable, life-like solutions for patients experiencing eye loss, thereby maintaining a competitive moat in a niche but essential medical field.
How much funding has Erickson Laboratories raised?
Erickson Laboratories has raised a total of $74K across 1 funding round:
Debt
$74K
Debt (2021): $74K with participation from PPP
Key Investors in Erickson Laboratories
PPP
Public-Private Partnership
What's next for Erickson Laboratories?
Looking ahead, the infusion of capital is expected to drive a strategic expansion of Erickson Laboratories' operational footprint. Given the current Series B/C stage, the firm is likely to prioritize the integration of advanced manufacturing technologies to improve prosthetic precision and patient comfort. Furthermore, the organization may explore opportunities to scale its clinical model into new geographic markets, leveraging its eighty-year reputation to capture additional market share. By focusing on operational efficiency and the continued professional development of its ocularist team, Erickson Laboratories is poised to solidify its status as a leader in the specialized ocular health industry, ensuring long-term sustainability and continued innovation in patient care.
See full Erickson Laboratories company page
